No decision was made by the FDA, but CBD manufacturers are on alert
The U.S. Food and Drug Administration’s first hearing on cannabidiol — CBD — left those involved in the booming new industry concerned for its future.
“In the 10 hours of testimony, I think the panel was given some good information and some bad information,” said Colleen Keahey Lanier, the executive director of the Hemp Industries Association. “So, it is a risk at this point.”
The hearing Friday was the FDA’s first step in determining how it will regulate CBD — a compound derived from the hemp plant that is being widely marketed and consumed across the country, but is unregulated.
In his opening remarks, acting FDA Commissioner Ned Sharpless expressed doubts about the compound’s safety.
To Read The Rest Of This Article On UPI, Click Here